Search hospitals > Maryland > Baltimore
University of Maryland/Greenebaum Cancer Center
Claim this profileBaltimore, Maryland 21201
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Breast Cancer
671 reported clinical trials
30 medical researchers
Summary
University of Maryland/Greenebaum Cancer Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Cancer, Leukemia, Lung Cancer, Lymphoma, Breast Cancer and other specialties. University of Maryland/Greenebaum Cancer Center is involved with conducting 671 clinical trials across 536 conditions. There are 30 research doctors associated with this hospital, such as Mark Mishra, MD, Ranee Mehra, MD, Teresa A. York, and Katherine Scilla, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Leukemia
Global LeaderStage II
Stage I
Stage IV
Top PIs
Mark Mishra, MDUniversity of Maryland/Greenebaum Cancer Center2 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
19 reported clinical trials
43 drugs studied
Ranee Mehra, MDUniversity of Maryland/Greenebaum Cancer Center5 years of reported clinical research
Expert in Cancer
Expert in Squamous Cell Carcinoma
21 reported clinical trials
54 drugs studied
Teresa A. YorkUniversity of Maryland/Greenebaum Cancer Center7 years of reported clinical research
Expert in Tumors
Studies Cancer
19 reported clinical trials
61 drugs studied
Katherine Scilla, MDUniversity of Maryland/Greenebaum Cancer Center4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
18 drugs studied
Clinical Trials running at University of Maryland/Greenebaum Cancer Center
Squamous Cell Carcinoma
Cancer
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Esophageal Carcinoma
Lung Cancer
Brain Tumor
Non-Small Cell Lung Cancer
Oropharyngeal Carcinoma
NRC-2694-A + Paclitaxel
for Head and Neck Cancer
This trial tests a new drug, NRC-2694-A, taken with paclitaxel, for patients with head and neck cancer that has come back or spread and did not respond to previous treatments. The new drug aims to block proteins that help cancer grow, while paclitaxel helps kill the cancer cells. Paclitaxel is a well-established drug known for its effectiveness in treating various cancers, including head and neck cancer. This combination could offer a new treatment option for these patients.
Recruiting3 awards Phase 2
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Proton Therapy vs Photon Radiation
for Esophageal Cancer
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Maryland/Greenebaum Cancer Center?
University of Maryland/Greenebaum Cancer Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Cancer, Leukemia, Lung Cancer, Lymphoma, Breast Cancer and other specialties. University of Maryland/Greenebaum Cancer Center is involved with conducting 671 clinical trials across 536 conditions. There are 30 research doctors associated with this hospital, such as Mark Mishra, MD, Ranee Mehra, MD, Teresa A. York, and Katherine Scilla, MD.
Where is University of Maryland/Greenebaum Cancer Center located?
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, situated at 22 S Greene St, Baltimore, MD 21201, is a key component of the University of Maryland Medical System. It provides outpatient care in the Roslyn and Leonard Stoler Pavilion, conveniently located inside the main hospital lobby. For new patient appointments, contact 410-328-7904 or 1-800-888-8823.
Who should I call to ask about financial aid or insurance network?
**University of Maryland/Greenebaum Cancer Center Financial and Insurance Assistance:**
- For financial assistance, visit the University of Maryland Faculty Physicians, Inc. financial assistance page.
- For insurance inquiries, contact the University of Maryland Medical System's Patient Assistance Line at 410-328-7609.
- For assistance with insurance and billing questions, call the Health Center staff at 301-314-8147.
What insurance does University of Maryland/Greenebaum Cancer Center accept?
The University of Maryland/Greenebaum Cancer Center accepts a wide range of insurance plans, including commercial health insurance, Medicaid, and Medicare. It is in network with Aetna, Blue Cross Blue Shield (excluding Omnia Silver), Carefirst, United Health Care, and Cigna's PPO and Open Access Plus products. Patients are encouraged to verify coverage with their insurance company before visiting, as certain services like x-ray and in-house laboratory services may not be covered under specific plans such as Maryland Medicaid and Carefirst Blue Choice.
What awards or recognition has University of Maryland/Greenebaum Cancer Center received?
The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCCC) is nationally recognized for its excellence in cancer treatment and research, holding a "comprehensive" designation from the National Cancer Institute (NCI). This places UMGCCC among the elite cancer centers in the United States, focusing on hormone responsive cancers, tumor immunology and immunotherapy, molecular and structural biology, and population science. Additionally, it is recognized as a Center of Excellence by various health insurance companies and national transplant networks for meeting or exceeding quality of care and patient survival benchmarks.